# The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART

> **NCT04612452** · — · COMPLETED · sponsor: **University of Bern** · enrollment: 2820 (actual)

## Conditions studied

- Hiv
- Drug Resistancy
- Virologic Failure

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04612452
- **Lead sponsor:** University of Bern
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-05
- **Primary completion:** 2023-03-22
- **Final completion:** 2023-03-22
- **Target enrollment:** 2820 (ACTUAL)
- **Last updated:** 2023-03-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04612452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04612452, "The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04612452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*